Look back at pharma news in the week to January 17, 2020

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

Licensing featured in the news last week, with Germany’s MorphoSys announcing a deal with USA-based Incyte to commercialize its B-cell malignancies candidate tafasitamab, and Biogen taking over an early-stage drug from Pfizer - PF-05251749 - which has potential for treating sleep disorders associated with Alzheimer’s and Parkinson’s disease. Also, UK-based Adaptimmune entered into a lucrative collaboration with Japan’s Astellas Pharma on cancer research. Elsewhere, Swiss giant Novartis’ novel arrangement with the UK’s National Health Service for access to its cardiovascular drug inclisiran attracted a fair amount of attention. On the M&A front, German biotech BioNTech said last Thursday it was buying USA-based Neon Therapeutics to boost its T-cell pipeline.

Solid deal with MorphoSys, but may not be viewed as transformative

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical